AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21450647 — intervention group
Group type: EXPERIMENTAL
Intervention: Duke Treadmill Score and VA Treadmill Scores
Number of subjects: 306
Study 19736331 — intervention group
Group type: EXPERIMENTAL
Intervention: Communities That Care (CTC) prevention system
Number of subjects: 4407
Study 19736331 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 4407
Study 17456506 — intervention group
Group type: EXPERIMENTAL
Intervention: Twin Block (TB) appliance
Number of subjects: 62
Study 17456506 — intervention group
Group type: COMPARATOR
Intervention: Dynamax appliance
Number of subjects: 62
Study 14746575 — intervention group
Group type: EXPERIMENTAL
Intervention: Nateglinide
Number of subjects: 14
Study 14746575 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide
Number of subjects: 14
Study 14746575 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 11414347 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational enhancement intervention with individual and housewide feedback components
Number of subjects: 120
Study 11414347 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual control condition
Number of subjects: 120
Study 9740261 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether 300 mg plus Pyrimethamine 100 mg
Number of subjects: 8
Study 9740261 — intervention group
Group type: COMPARATOR
Intervention: Artemether 300 mg
Number of subjects: 8
Study 9740261 — intervention group
Group type: COMPARATOR
Intervention: Pyrimethamine 100 mg
Number of subjects: 8
Study 8036963 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help smoking-cessation intervention
Number of subjects: 0
Study 2725087 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical algorithms (CA)
Number of subjects: 0
Study 2725087 — intervention group
Group type: COMPARATOR
Intervention: Prose
Number of subjects: 0
Study 30768192 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 174
Study 30768192 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-Centered Assessment and Counseling for Exercise (PACE)
Number of subjects: 174
Study 30768192 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 174
Study 30768192 — intervention group
Group type: COMPARATOR
Intervention: Comparison of MI and Control
Number of subjects: 174
Study 30768192 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of PACE and MI
Number of subjects: 174
Study 29191232 — intervention group
Group type: EXPERIMENTAL
Intervention: Active surveillance system
Number of subjects: 70
Study 29191232 — intervention group
Group type: COMPARATOR
Intervention: Passive surveillance system
Number of subjects: 70
Study 25480617 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertical periumbilical incision (VW)
Number of subjects: 40
Study 25480617 — intervention group
Group type: COMPARATOR
Intervention: Transverse left iliac fossa incision (TW)
Number of subjects: 40
Study 25480617 — intervention group
Group type: EXPERIMENTAL
Intervention: Both VW and TW
Number of subjects: 40
Study 23607501 — intervention group
Group type: EXPERIMENTAL
Intervention: TAFF (Separation Anxiety Family Therapy)
Number of subjects: 64
Study 23607501 — intervention group
Group type: COMPARATOR
Intervention: CC (Coping Cat)
Number of subjects: 64
Study 23607501 — intervention group
Group type: EXPERIMENTAL
Intervention: Both TAFF and CC
Number of subjects: 64
Study 21479682 — intervention group
Group type: EXPERIMENTAL
Intervention: Sivelestat administered until postoperative day (POD) 2 (Group A)
Number of subjects: 30
Study 21479682 — intervention group
Group type: EXPERIMENTAL
Intervention: Sivelestat administered until postoperative day (POD) 5 (Group B)
Number of subjects: 30
Study 21479682 — intervention group
Group type: COMPARATOR
Intervention: Historical controls without Sivelestat administration
Number of subjects: 30
Study 19783715 — intervention group
Group type: EXPERIMENTAL
Intervention: Phentermine 15 mg with Taranabant 0.5 mg
Number of subjects: 0
Study 19783715 — intervention group
Group type: EXPERIMENTAL
Intervention: Phentermine 15 mg with Taranabant 2 mg
Number of subjects: 0
Study 19783715 — intervention group
Group type: COMPARATOR
Intervention: Phentermine 15 mg without Taranabant
Number of subjects: 0
Study 19783715 — intervention group
Group type: EXPERIMENTAL
Intervention: Phentermine 15 mg with Taranabant 1 mg
Number of subjects: 0
Study 16981054 — intervention group
Group type: EXPERIMENTAL
Intervention: Transport with platelet GP IIb/IIIa receptor inhibitor (tirofiban; 10 mg/kg IV bolus followed by 0.1 mg/kg/min infusion during transport)
Number of subjects: 341
Study 16981054 — intervention group
Group type: COMPARATOR
Intervention: Thrombolytic therapy alone
Number of subjects: 341
Study 15063915 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity hospital programs
Number of subjects: 230
Study 15063915 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity programs
Number of subjects: 230
Study 15063915 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity programs
Number of subjects: 230
Study 15063915 — intervention group
Group type: COMPARATOR
Intervention: Hospital-based or community-based programs
Number of subjects: 230
Study 10649158 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based patient education methods (including the videocassette Commit to Quit During and After Pregnancy, the publication A Pregnant Woman's Guide to Quit Smoking, and a brief counseling session)
Number of subjects: 265
Study 10649158 — intervention group
Group type: COMPARATOR
Intervention: Standardized risk information and advice to quit smoking (Control group)
Number of subjects: 265
Study 9038856 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular human insulin at 2.0 mU.kg‐1.min‐1
Number of subjects: 0
Study 9038856 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular human insulin at 4.0 mU.kg‐1.min‐1
Number of subjects: 0
Study 8587082 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabumetone 1000-1500 mg po daily
Number of subjects: 382
Study 8587082 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac SR 100-150 mg po daily
Number of subjects: 382
Study 8587082 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabumetone
Number of subjects: 382
Study 2666249 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS 201-995 (octreotide, Sandostatin)
Number of subjects: 273
Study 2666249 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 273
Study 738150 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructional day-care program designed to prevent socioculturally caused mental retardation
Number of subjects: 0
Study 738150 — intervention group
Group type: COMPARATOR
Intervention: Nonintervention control group
Number of subjects: 0
Study 738150 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructional day-care program
Number of subjects: 0
Study 30837453 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 Hz‐tACS
Number of subjects: 32
Study 30837453 — intervention group
Group type: COMPARATOR
Intervention: 40 Hz‐tACS
Number of subjects: 32
Study 30837453 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 32
Study 28710373 — intervention group
Group type: EXPERIMENTAL
Intervention: Random alterations preserving degree distribution
Number of subjects: 0
Study 28710373 — intervention group
Group type: EXPERIMENTAL
Intervention: Different types of random alterations
Number of subjects: 0
Study 27281304 — intervention group
Group type: EXPERIMENTAL
Intervention: Menstralean (diet and exercise program tailored to menstrual cycle)
Number of subjects: 60
Study 27281304 — intervention group
Group type: COMPARATOR
Intervention: Control (simple energy restriction)
Number of subjects: 60
Study 23596006 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary injection of bone marrow-derived mononuclear cells (BM-MNC) early (5 to 7 days after MI)
Number of subjects: 200
Study 23596006 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary injection of bone marrow-derived mononuclear cells (BM-MNC) late (3 to 4 weeks after MI)
Number of subjects: 200
Study 23596006 — intervention group
Group type: COMPARATOR
Intervention: Control group (no BM-MNC treatment)
Number of subjects: 200
Study 21768729 — intervention group
Group type: EXPERIMENTAL
Intervention: Brochure presented before questionnaire
Number of subjects: 0
Study 21768729 — intervention group
Group type: COMPARATOR
Intervention: Brochure presented after questionnaire
Number of subjects: 0
Study 20143531 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (1.25 mg administered into the vitreous body)
Number of subjects: 56
Study 17117128 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-directed therapy
Number of subjects: 224
Study 17117128 — intervention group
Group type: COMPARATOR
Intervention: Non-goal-directed therapy
Number of subjects: 224
Study 14967062 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-TNF therapy
Number of subjects: 0
Study 14967062 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11342894 — intervention group
Group type: EXPERIMENTAL
Intervention: Crushed tablets
Number of subjects: 16
Study 11342894 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewed tablets
Number of subjects: 16
Study 11342894 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral solution
Number of subjects: 16
Study 11342894 — intervention group
Group type: COMPARATOR
Intervention: Whole tablets
Number of subjects: 16
Study 1833301 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg DHAS i.v. administration
Number of subjects: 8
Study 1833301 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 6623364 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP/IMV (high tidal volumes 12 to 18 ml/kg)
Number of subjects: 18
Study 6623364 — intervention group
Group type: COMPARATOR
Intervention: ZEEP/A-CM (low tidal volumes 8 to 10 ml/kg)
Number of subjects: 18
Study 31852061 — intervention group
Group type: EXPERIMENTAL
Intervention: Microendoscopic discectomy (MED)
Number of subjects: 60
Study 31852061 — intervention group
Group type: COMPARATOR
Intervention: Open discectomy (OLD)
Number of subjects: 60
Study 28174353 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg daily for 30 days
Number of subjects: 80
Study 28174353 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 26414343 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention including motivational interviewing and behavior change techniques
Number of subjects: 275
Study 26414343 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 275
Study 24293094 — intervention group
Group type: EXPERIMENTAL
Intervention: SQDL (squats and deadlifts)
Number of subjects: 22
Study 24293094 — intervention group
Group type: EXPERIMENTAL
Intervention: ABADD (standing hip abductions and adductions)
Number of subjects: 22
Study 24293094 — intervention group
Group type: EXPERIMENTAL
Intervention: COMBO (squat/deadlift and abduction/adduction)
Number of subjects: 22
Study 22854880 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocoa beverages (30-900 mg flavanol per day)
Number of subjects: 20
Study 22854880 — intervention group
Group type: COMPARATOR
Intervention: Green tea (matched to cocoa beverage for monomeric flavanol content)
Number of subjects: 20
Study 18634706 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week herring diet (150 g baked herring fillets/d, 5 d/week)
Number of subjects: 35
Study 18634706 — intervention group
Group type: COMPARATOR
Intervention: Reference diet (150 g baked lean pork and chicken fillets/d, 5 d/week)
Number of subjects: 35
Study 18634706 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week herring diet
Number of subjects: 35
Study 17961422 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (20 mg/d on top of standard therapy)
Number of subjects: 61
Study 17961422 — intervention group
Group type: COMPARATOR
Intervention: Control (standard therapy)
Number of subjects: 61
Study 15082429 — intervention group
Group type: EXPERIMENTAL
Intervention: Early discharge and rehabilitation service
Number of subjects: 370
Study 11819179 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotype resistance testing
Number of subjects: 142
Study 11819179 — intervention group
Group type: EXPERIMENTAL
Intervention: Expert advice with genotype data
Number of subjects: 142
Study 11819179 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenotype resistance testing
Number of subjects: 142
Study 11819179 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 142
Study 9824387 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide (1600 microg/day)
Number of subjects: 58
Study 9824387 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide (1600 microg/day) plus oral prednisolone (5 mg/day)
Number of subjects: 58
Study 9824387 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 7650226 — intervention group
Group type: EXPERIMENTAL
Intervention: 80-mg immediate-release (IR) tablet, phase A
Number of subjects: 12
Study 7650226 — intervention group
Group type: EXPERIMENTAL
Intervention: Two 80-mg IR tablets, phase B
Number of subjects: 12
Study 7650226 — intervention group
Group type: EXPERIMENTAL
Intervention: 160-mg controlled-release capsule, phase C
Number of subjects: 12
Study 7650226 — intervention group
Group type: COMPARATOR
Intervention: 10-mg IV bolus, phase D
Number of subjects: 12
Study 2192716 — intervention group
Group type: EXPERIMENTAL
Intervention: Dispersible tablets (2 X 150 mg)
Number of subjects: 12
Study 2192716 — intervention group
Group type: EXPERIMENTAL
Intervention: Film-coated tablets (2 X 150 mg)
Number of subjects: 12
Study 2192716 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 422304 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol
Number of subjects: 17
Study 422304 — intervention group
Group type: COMPARATOR
Intervention: Combination of propranolol and dihydrallazine
Number of subjects: 17
Study 30968987 — intervention group
Group type: EXPERIMENTAL
Intervention: RE-AIM framework implementation
Number of subjects: 72
Study 28411506 — intervention group
Group type: COMPARATOR
Intervention: Care As Usual (CAU)
Number of subjects: 166
Study 28411506 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational Prevention program (PEP)
Number of subjects: 166
Study 28411506 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychiatric Consultation followed by PEP (PC+PEP)
Number of subjects: 166
Study 28411506 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy followed by PEP (CBT+PEP)
Number of subjects: 166
Study 25256567 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard hemodiafiltration (HDF) with bicarbonate (34 mmol/L) and acetate dialysate (3 mmol/L)
Number of subjects: 22
Study 25256567 — intervention group
Group type: COMPARATOR
Intervention: Acetate-free biofiltration (AFB) without base in the dialysate
Number of subjects: 22
Study 25256567 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard hemodiafiltration (HDF)
Number of subjects: 22
Study 25256567 — intervention group
Group type: COMPARATOR
Intervention: Acetate-free biofiltration (AFB)
Number of subjects: 22
Study 23666460 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Number of subjects: 40
Study 23666460 — intervention group
Group type: COMPARATOR
Intervention: Sham RIPC (Control)
Number of subjects: 40
Study 21857144 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple antiplatelet therapy (TAT; addition of cilostazol to dual antiplatelet therapy)
Number of subjects: 900
Study 21857144 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (DAT)
Number of subjects: 900
Study 21857144 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of cilostazol to DAT
Number of subjects: 900
Study 21857144 — intervention group
Group type: COMPARATOR
Intervention: CCB without concomitant cilostazol use
Number of subjects: 900
Study 19232034 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin Aspart (IAsp)
Number of subjects: 322
Study 19232034 — intervention group
Group type: COMPARATOR
Intervention: Human Insulin (HI)
Number of subjects: 322
Study 17503066 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic ointment with hydrocortisone acetate (AB + HC)
Number of subjects: 151
Study 17503066 — intervention group
Group type: COMPARATOR
Intervention: Antibiotic ointment (AB)
Number of subjects: 151
Study 15025615 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 0.4 mg kg(‐1)
Number of subjects: 10
Study 15025615 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 2.5 mg kg(‐1)
Number of subjects: 10
Study 15025615 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 10
Study 11205522 — intervention group
Group type: EXPERIMENTAL
Intervention: Welfare-sponsored, government-funded job training
Number of subjects: 0
Study 11205522 — intervention group
Group type: COMPARATOR
Intervention: Nonparticipants (control group)
Number of subjects: 0
Study 9161392 — intervention group
Group type: EXPERIMENTAL
Intervention: DVT prophylaxis using low-dose heparin sodium therapy (5000 U every 12 hours) and calf-length intermittent mechanical compression devices
Number of subjects: 98
Study 9161392 — intervention group
Group type: COMPARATOR
Intervention: No DVT prophylaxis
Number of subjects: 98
Study 7954768 — intervention group
Group type: EXPERIMENTAL
Intervention: Excimer laser coronary angioplasty (ELCA) alone
Number of subjects: 29
Study 7954768 — intervention group
Group type: EXPERIMENTAL
Intervention: Excimer laser coronary angioplasty (ELCA) plus balloon dilatation
Number of subjects: 29
Study 7954768 — intervention group
Group type: COMPARATOR
Intervention: PTCA alone
Number of subjects: 29
Study 7954768 — intervention group
Group type: EXPERIMENTAL
Intervention: Excimer laser coronary angioplasty (ELCA)
Number of subjects: 29
Study 2881573 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (5 mg)
Number of subjects: 39
Study 2881573 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone (5 or 10 mg)
Number of subjects: 39
Study 2881573 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 28838263 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) 10-15 mg/week for minimum 12 weeks
Number of subjects: 21
Study 28838263 — intervention group
Group type: COMPARATOR
Intervention: Control (healthy subjects)
Number of subjects: 21
Study 26743808 — intervention group
Group type: EXPERIMENTAL
Intervention: Forming implementation intentions with a 'volitional help sheet'
Number of subjects: 226
Study 26743808 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-generating implementation intentions without help
Number of subjects: 226
Study 26743808 — intervention group
Group type: COMPARATOR
Intervention: Thinking about triggers and coping, but not forming implementation intentions
Number of subjects: 226
Study 26520413 — intervention group
Group type: EXPERIMENTAL
Intervention: Prebiotic supplementation with inulin (10 g/day)
Number of subjects: 48
Study 26520413 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 22793877 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured birth planning and travel facilitation
Number of subjects: 29295
Study 22793877 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured birth planning
Number of subjects: 29295
Study 22793877 — intervention group
Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 29295
Study 18823395 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg zoledronate i.v. every 3 months for 2 years (8 infusions)
Number of subjects: 22
Study 18823395 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo) every 3 months for 2 years (8 infusions)
Number of subjects: 22
Study 18823395 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 22
Study 17448044 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive programmes (group followed-up every 2 months)
Number of subjects: 400
Study 17448044 — intervention group
Group type: COMPARATOR
Intervention: Professional tooth cleaning
Number of subjects: 400
Study 17448044 — intervention group
Group type: EXPERIMENTAL
Intervention: Any of the test programmes
Number of subjects: 400
Study 15125825 — intervention group
Group type: COMPARATOR
Intervention: Insulin in addition to unchanged oral hypoglycemic medication (IC group)
Number of subjects: 64
Study 15125825 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin monotherapy (IM group)
Number of subjects: 64
Study 12563567 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 2 mg o.d.
Number of subjects: 280
Study 12563567 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 4 mg o.d.
Number of subjects: 280
Study 12563567 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 8 mg o.d.
Number of subjects: 280
Study 9839267 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol group
Number of subjects: 0
Study 9839267 — intervention group
Group type: COMPARATOR
Intervention: Nonprotocol group
Number of subjects: 0
Study 7734797 — intervention group
Group type: EXPERIMENTAL
Intervention: Human milk
Number of subjects: 0
Study 7734797 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula C (similar to B with added marine oil)
Number of subjects: 0
Study 7734797 — intervention group
Group type: COMPARATOR
Intervention: Formula A (based on corn oil)
Number of subjects: 0
Study 7734797 — intervention group
Group type: COMPARATOR
Intervention: Formula B (based on soy oil supplying LNA)
Number of subjects: 0
Study 2643865 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 93
Study 2643865 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 93
Study 4602827 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbenicillin indanyl sodium
Number of subjects: 61
Study 4602827 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin
Number of subjects: 61
Study 4602827 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephalexin
Number of subjects: 61
Study 30461597 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-test instructions developed by the Health Outcomes through Motivation and Education Project and a photo story information brochure about cervical cancer
Number of subjects: 103
Study 30461597 — intervention group
Group type: COMPARATOR
Intervention: Self-test instructions developed by the device manufacturer and a standard information brochure about cervical cancer
Number of subjects: 103
Study 28974305 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided SGB (n = 20) with a 6-mL injection of 1% lidocaine
Number of subjects: 40